157 related articles for article (PubMed ID: 24720787)
21. Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates.
Huan M; Tian S; Cui H; Zhang B; Su D; Wang J; Li K; Cao W
Biomed Res Int; 2013; 2013():926584. PubMed ID: 24381947
[TBL] [Abstract][Full Text] [Related]
22. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
23. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
Lee ES; Na K; Bae YH
J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
[TBL] [Abstract][Full Text] [Related]
27. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
28. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
29. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
[TBL] [Abstract][Full Text] [Related]
30. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
31. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy.
Lai PS; Lou PJ; Peng CL; Pai CL; Yen WN; Huang MY; Young TH; Shieh MJ
J Control Release; 2007 Sep; 122(1):39-46. PubMed ID: 17628166
[TBL] [Abstract][Full Text] [Related]
33. QbD-based development of α-linolenic acid potentiated nanoemulsion for targeted delivery of doxorubicin in DMBA-induced mammary gland carcinoma: in vitro and in vivo evaluation.
Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
Drug Deliv Transl Res; 2018 Oct; 8(5):1313-1334. PubMed ID: 29748834
[TBL] [Abstract][Full Text] [Related]
34. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
[TBL] [Abstract][Full Text] [Related]
35. In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid.
Huan M; Cui H; Teng Z; Zhang B; Wang J; Liu X; Xia H; Zhou S; Mei Q
Biosci Biotechnol Biochem; 2012; 76(8):1577-9. PubMed ID: 22878199
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin-tethered fluorescent silica nanoparticles for pH-responsive anticancer drug delivery.
Zhang P; Kong J
Talanta; 2015 Mar; 134():501-507. PubMed ID: 25618700
[TBL] [Abstract][Full Text] [Related]
37. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
38. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
39. A tumor-targeted, intracellular activatable and theranostic nanodiamond drug platform for strongly enhanced in vivo antitumor therapy.
Du X; Li L; Wei S; Wang S; Li Y
J Mater Chem B; 2020 Feb; 8(8):1660-1671. PubMed ID: 32011619
[TBL] [Abstract][Full Text] [Related]
40. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
